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Background: Improved mesothelioma patient survival will require development of novel and more effective pharmacological
interventions. TP53 genomic mutations are uncommon in mesothelioma, and recent data indicate that p53 remains functional, and
therefore is a potential therapeutic target in these cancers. In addition, the tumour suppressor NF2 is inactivated by genomic
mechanisms in more than 80% of mesothelioma, causing upregulation of FAK activity. Because FAK is a negative regulator of p53,
NF2 regulation of FAK–p53–MDM2 signalling loops were evaluated.
Methods: Interactions of FAK–p53 or NF2–FAK were evaluated by phosphotyrosine-p53 immunoaffinity purification and tandem
mass spectrometry, and p53, FAK, and NF2 immunoprecipitations. Activation and/or expression of FAK, p53, and NF2 were also
evaluated in mesotheliomas. Effects of combination MDM2 and FAK inhibitors/shRNAs were assessed by measuring
mesothelioma cell viability/growth, expression of cell cycle checkpoints, and cell cycle alterations.
Results:We observed constitutive activation of FAK, a known negative regulator of p53, in each of 10 mesothelioma cell lines and each of
nine mesothelioma surgical specimens, and FAK was associated with p53 in five of five mesothelioma cell lines. In four mesotheliomas with
wild-type p53, FAK silencing by RNAi induced expression and phosphorylation of p53. However, FAK regulation of mesothelioma
proliferation was not restricted to p53-dependent pathways, as demonstrated by immunoblots after FAK knockdown in JMN1B
mesothelioma cells, which have mutant/inactivated p53, compared with four mesothelioma cell lines with nonmutant p53. Additive effects
were obtained through a coordinated reactivation of p53, by FAK knockdown/inhibition and MDM2 inhibition, as demonstrated by
immunoblots, cell viability, and cell-cycle analyses, showing increased p53 expression, apoptosis, anti-proliferative effects, and cell-cycle
arrest, as compared with either intervention alone. Our results also indicate that NF2 regulates the interaction of FAK–p53 and MDM2–p53.
Conclusions: These findings highlight novel therapeutic opportunities in mesothelioma.
Mesothelioma is a locally aggressive and highly lethal neoplasm,
linked epidemiologically to asbestos exposure (Craighead and
Mossman, 1982; Jongsma et al, 2008), and SV40 virus infection
(Carbone et al, 1994), in which the neoplastic proliferation
originates from pleural, peritoneal, or – rarely – pericardial
mesothelial cells. Pathologically, mesothelioma histological
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subtypes are epithelioid, spindle-cell, and mixed (epithelioid and
spindled; Janne et al, 2002), of which the spindled type has the
worst prognosis. Conventional chemotherapies and radiation
therapy have limited efficacy against mesothelioma, and substantial
improvements in survival will require development of novel and
more effective pharmacological interventions. A better under-
standing of mesothelioma biology – including the function of
highly recurrent mutations such as NF2 (Bianchi et al, 1995) and
BAP1 (Bott et al, 2011; Testa et al, 2011), and key growth factor
signalling pathways – will likely be useful in identifying biologically
rational targets for novel therapies.
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase
that mediates signalling through several downstream pathways,
leading to cell migration, growth factor signalling, cell cycle
progression, and cell survival (Lim et al, 2008; Ding et al, 2010;
Huang et al, 2010; Long et al, 2010). Furthermore, FAK has a
prominent role in integrin and receptor tyrosine kinase (RTK)
signalling (Parsons, 2003). Although FAK itself has not been
demonstrated to be an oncogene, FAK overexpression has been
reported in tumours of various tissue origins, especially in invasive
and metastatic tumours (Gabarra-Niecko et al, 2003). The effects
of FAK on tumour growth in mice suggest that FAK may influence
the formation, growth, and metastasis of tumours (Gabarra-Niecko
et al, 2003; Slack-Davis et al, 2009). There is increasing evidence to
indicate that FAK has an important role in regulating cell cycle
progression through cyclin D1 transcription, p27 expression, and
MAPK activation (Zhao et al, 2001; Ding et al, 2005). The tumour
suppressor p53 was first linked with FAK by Ilic et al (Ilic et al,
1998) and a p53 binding site has been identified in the FAK
promoter (Golubovskaya et al, 2004). Recently, studies of direct
interaction of the N-terminal domain of FAK with the N-terminal
transactivation domain of p53, particularly at the 7-amino-acid site
in the proline-rich region of the p53 N-terminal domain, indicated
that FAK can suppress p53-mediated apoptosis and inhibit the
transcriptional activity of p53 (Golubovskaya et al, 2005;
Golubovskaya et al, 2008). FIP200, a FAK inhibitor, has been
shown to induce cell cycle arrest by increasing the expression and
phosphorylation of p53 in human breast cancer cells (Melkoumian
et al, 2005). FAK inactivates p53 in a kinase-independent manner
through the FAK FERM domain, which acts as a scaffold to
enhance MDM2-dependent p53 ubiquitination. Importantly, p53
regulation is dependent on FAK nuclear translocation (Lim et al,
2008). These observations suggest that FAK regulates cell cycle
progression in a p53-dependent manner. However, it is still unclear
whether the FAK–p53 cell survival pathway may also have a role in
promoting tumour progression.
Mouse double minute 2 (MDM2) is an oncoprotein, the
primary E3 ubiquitin ligase responsible for ubiquitination and
degradation of p53 (Brooks and Gu, 2006). The structure of
MDM2 bound to p53 and the molecular mechanisms of the
interaction between MDM2 and p53 have been well characterised
(Kussie et al, 1996; Schon et al, 2002; Chene, 2003; White et al,
2006). Thus, inhibition of the MDM2–p53 interaction by small
molecules is an attractive therapeutic opportunity in oncology.
Nutlin-3, a specific small-molecule inhibitor of MDM2, suppresses
the interaction of MDM2 with wild-type p53, activating its
anticancer activity (Kojima et al, 2006; Tovar et al, 2006; Van
et al, 2009; Moran and Maki, 2010). Nutlin-3 shows strong
antitumour effects in mice, with few side effects on normal tissues
(Brummelkamp et al, 2006), indicating that tumours with wild-
type p53 may be susceptible to inhibition of the MDM2–p53
interaction. Recently, we found that wild-type p53 depletion by
histone deacetylase inhibitors was MDM2 amplification-dependent
(Ou et al, 2015), and inhibition of PI3K/AKT was also associated
with MDM2–p53 cell cycle regulation (Zhou et al, 2014).
TP53 mutations are seen infrequently in mesothelioma (Metcalf
et al, 1992; Papp et al, 2001). Recent data also indicate that p53 is
functional in the absence of p14ARF and, if reactivated, can induce
apoptosis in mesothelioma (Hopkins-Donaldson et al, 2006).
Suppressor of cytokine signalling 3 (SOCS3) overexpression
showed anti-proliferative effects in mesotheliomas via multiple
signalling pathways including JAK/STAT3 and FAK/p53 (Iwahori
et al, 2011). Increasing p53 expression enhances cytotoxicity of the
first-line chemotherapeutics cisplatin or pemetrexed in p53-wild-
type mesothelioma (Li et al, 2012).
The NF2 (merlin) is a tumour-suppressor protein, inactivated
by genomic mechanisms in more than 80% of mesothelioma; these
are crucial events in mesothelioma pathogenesis, and result in
hyperactivation of FAK (Bianchi et al, 1995; Poulikakos et al,
2006). Recent studies showed that NF2 deficiency predicts
increased sensitivity of mesothelioma cells to a FAK inhibitor,
VS-4718 (Shapiro et al, 2014). In addition, previous data have
demonstrated that NF2 neutralises the inhibitory effect of MDM2
on p53 (Kim et al, 2004).
In the present study, we investigated interaction of FAK and p53
through a functional proteomic approach including phosphotyr-
osine and p53 immunoprecipitation double immunoaffinity
purification, and tandem mass spectrometry. The expression and
phosphorylation of FAK and p53 were also evaluated in
mesothelioma cell lines and primary tumours. We evaluated the
effects of coordinated reactivation of p53, and our findings
highlight novel therapeutic opportunities in mesothelioma.
MATERIALS AND METHODS
Antibodies and reagents. Polyclonal antibody to FAK, and
monoclonal antibodies to phosphotyrosine (PY99), p53, PARP, and
NF2 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Monoclonal mouse antibodies to MDM2 and p21, and polyclonal
antibody to phospho-FAK (Y397) were from Zymed Laboratories
(Invitrogen Life Technologies, Carlsbad, CA, USA). Polyclonal
antibodies to phospho-p53 (Ser15) and phospho-NF2 (Ser518) were
from Cell Signaling Technology (Beverly, MA, USA). Phospho-FAK
(Y861) was obtained from Biosource (Invitrogen Life Technologies).
We obtained monoclonal mouse antibodies to cyclin A from
Novocastra (Newcastle upon Tyne, UK), and b-actin and GAPDH
from Sigma-Aldrich (St Louis, MO, USA).
Mouse anti-phosphotyrosine (PY)-sepharose 4B, Protein A- and
Protein G-sepharose beads were from Zymed Laboratories.
NOVEX Coomassie colloidal blue stain kit, NuPAGE TM 4–12%
Bis-Tris Gel, Lipofectamine and Plus reagent were obtained from
Invitrogen Life Technologies. Phenyl phosphate and polybrene
were from Sigma. Nutlin-3 and PF562271 were obtained from LC
Labs (Woburn, MA, USA) and Symansis (Auckland, NZ, USA),
respectively. Lentiviral NF2 shRNAs were from Sigma. NF2
shRNA1: 50-CCGGCGGGCTTTGTTTCCTTCTTTACTCGAGTA
AAGAAGGAAACAAAGCCCGTTTTTG-30; NF2 shRNA2: 50-CC
GGGCTTCGTGTTAATAAGCTGATCTCGAGATCAGCTTAT-
TAACACGAAGCTTTTTG-30.
Mesothelioma cell lines and frozen tumour specimens. Eight
mesothelioma cell lines were established from surgical materials
from previously untreated patients, as reported previously
(Ou et al, 2011). The MESO59, MESO257, MESO542, and
MESO924 cell lines were established from epithelial-type mesothe-
liomas, MESO296, MESO589, and MESO647 from mixed-histology
mesotheliomas, and MESO428 from a spindle-cell mesothelioma. An
additional mesothelioma cell line, JMN1B, was established from an
epithelial-type mesothelioma (Demetri et al, 1989). Derivation of each
cell line from the corresponding surgical specimen was corroborated
by STR profiling (Supplementary Table 1). All mesothelioma frozen
tumour specimens were discarded tissues, obtained from Brigham
and Women’s Hospital. The Brigham and Women’s Hospital
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Institutional Review Board approved the experiments, and
informed consent was obtained from all the subjects.
Phosphotyrosine-p53 immunoaffinity purification and tandem
mass spectrometry. Tyrosine kinases (TKs) were immunopreci-
pitated from mesothelioma cell lysates using a p53 monoclonal
antibody, and subsequently immunoblotted and stained for
phosphotyrosine (PY99) to identify the molecular mass of putative
activated TKs, which interacted with p53. Candidate-activated TKs
were then characterised from the MESO257 cell line by mass
spectrometry. Activated proteins were purified on a phosphotyr-
osine (PY) immunoaffinity column in which 0.5ml of sepharose-
conjugated anti-PY was loaded in a 10ml polypropylene column
and washed with a 5X volume of 1 PBS containing 0.02%
sodium azide. The column was pre-equilibrated with a 5X volume
of lysis buffer, then incubated with 10mg of protein lysates at 4 1C
with overnight end-over-end mixing. The flow-through fraction
was collected and reloaded on the column 10 times. The column
was then washed with 1ml lysis buffer five times, and the tyrosine-
phosphorylated proteins were eluted with 1ml 100mM phenyl
phosphate in lysis buffer 10 times. The eluates were dialysed
against 1 litre of 1 PBS buffer overnight at 4 1C. The sample was
then concentrated to B100 ml of final volume using centricon
filters (Millipore Corporation, Bedford, MA, USA). Ninety-six
percent of the eluates were immunoprecipitated by antibody to
p53. Finally, 4% of the eluates and 15% of the PY-p53 fractions
were immunoblotted and stained for phosphotyrosine, while the
remaining 85% of the PY-p53 fractions were gel electrophoresed
and stained using a NOVEX Coomassie colloidal blue stain kit
protocol. A strongly phosphorylated protein band at 130 kDa was
excised from the Coomassie gel, and protein sequences were
determined by mass spectrometry. The blots were then stripped
and restained with specific antibodies to validate candidate tyrosine
kinases.
Western blotting analysis. Whole-cell lysates were prepared using
lysis buffer (1% NP-40, 50mM Tris-HCl pH 8.0, 100mM sodium
fluoride, 30mM sodium pyrophosphate, 2mM sodium molybdate,
5mM EDTA, and 2mM sodium orthovanadate) containing protease
inhibitors (10 mgml 1 aprotinin, 10 mgml 1 leupeptin, and 1mM
phenylmethylsulfonyl fluoride). Frozen tumour samples were diced
into small pieces in cold lysis buffer on dry ice and homogenised
using a Tissue Tearor (Model 398, Biospec Products, Inc.,
Bartlesville, OK, USA) for 2 s, —three to five times, on ice, and
the cell lysate was then rocked overnight at 4 1C. The lysates were
cleared by centrifugation at 14 000 g for 20min at 4 1C, and lysate
protein concentrations were determined using a Bio-Rad protein
assay (Bio-Rad Laboratories Hercules, CA, USA). Nuclear,
membrane, and cytoplasmic fraction lysates were prepared by
using a Qproteome Cell Compartment Kit (Qiagen Inc., Valencia,
CA, USA) according to the manufacturer’s protocol. Electrophor-
esis and western blotting were performed as described previously
(Rubin et al, 2001). The hybridisation signals were detected by
chemiluminescence (ECL, Amersham Pharmacia Biotechnology,
Marlborough, MA, USA) and captured using a FUJI LAS1000-plus
chemiluminescence imaging system.
Immunoprecipitation. Sepharose-protein A to rabbit polyclonal
antibodies and Sepharose-protein G to mouse monoclonal
antibodies were used. One milligram of protein lysates (500ml)
was preadsorbed for 30min using 20 ml of protein A or protein G
beads at 4 1C. Two micrograms of primary antibodies against FAK,
p53, or NF2 were rocked with the lysates for 2 h at 4 1C. Then 20ml
of sepharose-protein A or -protein G beads were added and rocked
overnight at 4 1C, then centrifuged at 10 000 g for 2min at 4 1C,
after which the sepharose beads were washed three times with
750 ml of IP buffer (25min each time) and once with 750 ml 10mM
Tris-Cl buffer (pH 7.6). Loading buffer (20 ml) was added to the
beads and boiled for 5min at 95 1C.
Lentiviral FAK shRNA constructs and virus preparation. The
pLKO.1puro (7 kb) lentivirus construct contains an U6 promoter
and HIV-1 RNA packaging signal with a puromycin- and
ampicillin-resistant element cloned 30 of the human phosphogly-
cerate kinase (hPGK) promoter. A cpptCTE was inserted 50 of the
hPGK promoter. Human FAK shRNA constructs were generated
by ligating the following oligomers into the unique AgeI and EcoRI
sites of pLKO.1puro: FAK forward 50-CCGGCCGGTCGAATGA-
TAAGGTGTACTCGAGTACACCTTATCATTCGACCGGTTTT
TG-30 and reverse 50-AATTCAAAAACCGGTCGAATGATAAGG
TGTACTCGAGTACACCTTATCATTCGACCGG-30.
Lentivirus preparations were produced by cotransfecting
pLKO.1puro with FAK or NF2 shRNA and helper virus packaging
plasmids pCMVDR8.91 and pMD.G (at a 10 : 10 : 1 ratio) into
293T cells. Transfections were carried out using Lipofectamine
and PLUS reagent. Lentiviruses were harvested at 24, 36, 48,
and 60 h post transfection. The virus was frozen at  80 1C in
appropriately sized aliquots for infection. Well-validated shRNAs
were used for FAK and NF2 knockdowns.
Cell culture and virus infection. Mesothelioma cells were
cultured in RPMI 1640 media with 15% fetal bovine serum
(FBS) and seeded in six-well plates. Lentiviral shRNA infections
were carried out in the presence of 8 mgml 1 polybrene. The cells
were lysed for western blot analysis or harvested for cell cycle
analysis at 96 h post infection. The MESO257 cells were selected
for stable expression of the NF2 shRNAs using 2 mgml 1
puromycin.
Cell viability analysis. MESO924, MESO257, MESO296,
MESO428, JMN1B, and stably infected MESO257 with NF2
shRNA knockdown were plated at 3000 cells per well in a 96-well
flat-bottomed plate (Falcon, Lincoln, NJ, USA) and cultured in
RPMI 1640 for 24 h before transduction with lentiviral empty
vector or FAK shRNA, or treatment with MDM2 inhibitor nutlin-3
and FAK inhibitor PF562271, or 48 h before treatment with nutlin-
3 after FAK shRNA transduction. Proliferation studies were carried
out after 3 or 6 days using the CellTiter-Glo luminescent assay
from Promega (Madison, WI, USA), and quantified using a Veritas
Microplate Luminometer from Turner Biosystems (Sunnyvale,
CA, USA). The data were normalised to the empty vector group or
DMSO. All the assays were performed in quadruplicate wells,
and were averaged from two independent experiments for each
cell line.
Cell cycle analysis. MESO924, MESO257, MESO296, MESO428,
and JMN1B cells in six-well plates were trypsinised and washed
with Hanks Balanced Salt Solution at room temperature after
infection with lentivirus for 72 h and/or treatment with nutlin-3 for
48 h. For nuclear staining, a DAPI-containing solution (nuclear
isolation and staining solution, NPE systems, Pembroke Pines, FL)
was added to the cells and the cell suspension was immediately
analysed in a flow cytometer (NPE Quanta, NPE Systems). Data
analyses were performed using Modfit LT software 3.1 (Verity
Software House, Topsham, ME, USA).
NF2 S518 point mutagenesis. Human NF2 full-length cDNA
expression plasmid (Catalogue: TC124024) was obtained from
Origene (Rockville, MD, USA). QuikChange Lightning Site-
Directed Mutagenesis Kit was from Agilent Technologies (Santa
Clara, CA, USA). NF2 S518A forward primer: 50-actgacatgaagcgg
cttgccatggagatagaga-30 reverse primer: 50-tctctatctccatggcaagccgctt-
catgtcagt-30 NF2 S518D forward primer: 50-aagatactgacatgaagcggctt
gacatggagatagagaaagaaaaag-30 reverse primer: 50-ctttttctttctctatctc-
catgtcaagccgcttcatgtcagtatctt-30. The NF2 mutation was validated
by sequencing.
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Statistical analysis. Student’s t-tests were performed on data from
cells treated with control DMSO or inhibitors, as well as cells
treated with empty vector or FAK shRNA. Statistically significant
differences between untreated control and treatment were defined
as *Po0.05, **Po0.01, and ***Po0.001.
RESULTS
FAK non-receptor tyrosine kinase is strongly activated and
interacts with p53 in mesothelioma. Phosphotyrosine eluates,
phosphotyrosine-p53 fractions, and p53 immunoprecipitations
were prepared from the MESO257 cell line, and phosphotyrosine
stains demonstrated B130 kDa proteins in immunoblot prepara-
tions (Figure 1). Mass spectrometry analysis of theB130 kDa band
cut from a Coomassie-stained gel identified the FAK non-receptor
tyrosine kinase. This finding was confirmed by subsequent
stripping of the immunoblots and restaining for FAK (Figure 1).
The p53 immunoblotting was not shown because of overlay of p53
and immunoglobulin heavy chain.
Using MESO924 as an internal standard, the phosphorylation
and expression of FAK and p53 were evaluated by immunoblotting
in mesothelioma cell lines and primary tumours. FAK and p53 were
expressed in most mesotheliomas, with especially strong expression
of p53 in JMN1B and one frozen tumour, both of which have been
found to contain TP53 missense mutations (JMN1B: G245S;
MESO96–975: A159V) (Figure 2). Focal adhesion kinase (phos-
pho-FAK Y397) was constitutively activated in all mesotheliomas.
The NF2 was weakly expressed in most frozen tumours, in which
the residual NF2 expression likely originated from nonneoplastic
cells in the specimens, whereas expression was nearly undetectable
in mesothelioma cell lines except for MESO257 (Figure 2).
We investigated the FAK–p53 interaction in mesothelioma cell
lines by FAK and p53 immunoprecipitations, followed by FAK
immunostaining (Figure 3). The p53 immunoprecipitations
revealed a dominant FAK 130 kDa band in five mesothelioma cell
lines, which was confirmed by FAK immunostaining in FAK
immunoprecipitations (Figure 3).
FAK shRNA knockdown or kinase inhibition results in
upregulation of p53. The FAK shRNA-mediated knockdown
resulted in B60–70% inhibition of FAK protein expression in
MESO257 at 48 h and 96 h post infection (Figure 4A). Treatment
with FAK inhibitor PF562271 decreased expression of phospho-
FAK, phospho-MDM2, and MDM2 in MESO257 and MESO296 in
a dose-dependent manner (Figure 4B and Supplementary
Figure 1). Interestingly, FAK shRNA knockdown or activity
inhibition induced two- to three-fold upregulation of phospho-
p53 and p53, indicating that FAK regulates p53 (Figure 4). The p53
expression quantifications were normalised to control transfections
using empty vector pLKO or DMSO.
Combination inhibition of the FAK–p53 and MDM2–p53
interactions suppressed cell viability in mesothelioma. Additive
effects on p53 expression were obtained through coordinated
dysregulation of p53, as demonstrated by immunoblots, after FAK
shRNA knockdown and MDM2 inhibition. Inhibition of FAK–p53
and MDM2–p53 interactions were evaluated in five mesothelioma
cell lines including MESO924, MESO257, MESO296, MESO428,
and JMN1B, at 48 h after treatment with nutlin-3 and/or at 72 h
post infection with FAK shRNA (Figure 5A). JMN1B is a control
cell line, which has mutant/inactivated p53. The expression of
MDM2, p53, and phospho-p53 increased in a dose-dependent
manner after treatment with nutlin-3 in cells with wild type p53
(MESO924, MESO257, MESO296, and MESO428). Similarly, p53
expression and phosphorylation increased after FAK shRNA
knockdown in these cells. Phospho-p53 and total p53 expression
quantifications were normalised to DMSO-treated cells. Combina-
tion of FAK knockdown and MDM2–p53 inhibition by nutlin-3
induced greater p53, phospho-p53, and CDK inhibitor p21
expression, and inhibited proliferation marker cyclin A expression,
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more effectively compared to either intervention alone (Figure 5A).
By contrast, expression and phosphorylation of p53 did not
increase in JMN1B after treatment with nutlin-3 and FAK shRNA
either alone or in combination. However, FAK shRNA knockdown
inhibited cyclin A proliferation marker expression in JMN1B cells
(Figure 5A).
Additive effects on cell viability and cell cycle inhibition were
obtained through coordinated dysregulation of p53 after FAK and
MDM2 inhibition. FAK knockdown in wild-type p53 mesothe-
lioma cell lines MESO924, MESO257, MESO296, and MESO428
resulted inB15–35% inhibition of cell viability at 3 days after FAK
silencing, compared with an empty vector control (Figure 5B).
In p53 wild-type cells, the most striking reduction in cell viability
(20–50%) was seen after treatment with nutlin-3 (Figure 5B).
However, viability was little affected in p53 mutant JMN1B cells
after treatment with nutlin-3 (Figure 5B). To determine whether
FAK kinase activity regulates mesothelioma viability, the FAK
kinase was inactivated using a small molecule inhibitor, PF562271.
Treatment with PF562271 showed profound anti-proliferative
effects at day 6 in all the five mesothelioma cell lines (Figure 5C).
Combination of FAK shRNA (day 3) or FAK inhibition (PF562271,
day 6) and MDM2 inhibition resulted in 20–77% or 80–90%
reduction in viability for these lines, respectively (Figure 5B and C).
Interestingly, FAK shRNA knockdown or FAK kinase inhibition
resulted in B90% or 50% viability reduction in JMN1B cells,
respectively (Figure 5B and C).
The FAK knockdown in all the five mesothelioma cell lines
resulted in G1 arrest. The G1 peaks were 54% (MESO924), 52%
(MESO257), 61% (MESO296), 48% (MESO428), and 36%
(JMN1B) in the empty vector-treated cells compared with 64%
(MESO924), 62% (MESO257), 70% (MESO296), 65% (MESO428),
and 40% (JMN1B) in FAK shRNA knockdown cells (Figure 5D and
Table 1). The cell cycle analyses also demonstrated a G1 block with
a decrease in the S-phase population after MDM2 inhibition by
nutlin-3 in wild-type p53 mesothelioma cell lines (Figure 5D and
Table 1). The combination of FAK shRNA and MDM2 inhibition
resulted in a G1/G2 block in cell cycle for these lines (Figure 5D
and Table 1). The FAK knockdown also induced apoptosis in
JMN1B: nuclear fragmentation was demonstrated in 4.6% cells
treated with empty vector control, but in 13% cells treated with
FAK shRNA (Figure 5D and Table 1).
NF2 regulates the FAK–p53 and MDM2–p53 interaction. The
observations of mild upregulation of p53 by FAK shRNA
knockdown in MESO257 (Figure 5A) with strong NF2 expression
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Figure 5. Additive effects of coordinated dysregulation of p53, as demonstrated by immunoblotting (A), cell viability (B and C) and cell cycle
analyses (D), showing that FAK and MDM2 inhibition induced greater p53 expression, anti-proliferative effects, and cell cycle arrest, as
compared to either intervention alone. (A) FAK, MDM2, phospho-p53, p53, p27, and cyclin A were evaluated by immunoblotting at 72 h post-
infection with FAK shRNA and/or 48 h after treatment with nutlin-3. Actin staining is a loading control. Phospho-p53 and p53 expression
quantitations are standardised to the DMSO or empty vector control. (B and C) Cell viability was evaluated by a Cell-titer Glo ATP-based
luminescence assay in wild type p53 mesothelioma cell lines (MESO924, MESO257, MESO296, and MESO428), and in mutant p53 mesothelioma
cell line (JMN1B), at 72 h post-infection with FAK shRNA and/or 48 h after treatment with nutlin-3 (B) or 6 days after treatment with nutlin-3 and
PF562271 (C). Data were normalised to empty lentivirus infections or DMSO, and represent the mean values (±s.d.) from quadruplicate cultures.
Statistically significant differences between untreated control and treatments or between empty vector control and FAK shRNA are presented as
*Po0.05, **Po0.01, ***Po0.001. (D) Cell cycle analyses were performed 72h after transduction with lentiviral FAK shRNA constructs and/or 48 h
after treatment with nutlin-3. MESO924, MESO257, MESO296, MESO428, and JMN1B cells show substantial G1 and G2-block after FAK silencing
and inhibition of the MDM2–p53 interaction, as compared with empty vector or DMSO control. JMN1B shows substantial nuclear fragmentation
after FAK silencing.
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(Figure 2), as compared with strong induction of p53 expression
after FAK knockdown in NF2-null mesothelioma cell lines
(Figure 5A), suggests that the FAK–p53 interaction is regulated
by NF2. The NF2 overexpression (wild-type and constitutive
activated mutation NF2 S518A) inhibits FAK phosphorylation in
NF2-null mesothelioma cell line (MESO924), but not loss-of-
function mutant NF2 S518D (Supplementary Figure 2), which is in
keeping with previous evidence for regulation of FAK activity by
NF2 (Poulikakos et al, 2006). We therefore evaluated the
interaction of NF2 with FAK in MESO257, which expresses NF2
strongly. The NF2–FAK interaction in MESO257 was evaluated by
NF2 and FAK immunoprecipitations followed by NF2 and FAK
immunoblotting (Figure 6A). The NF2 immunoprecipitations
revealed a dominant FAK 130 kDa band, and FAK IP revealed a
weak NF2 band (Figure 6A). Co-localisation of NF2, FAK, p53,
and MDM2 was evaluated by isolation of membrane, cytoplasm,
and nucleus fractions in MESO257 (Figure 6B). The NF2, p53, and
MDM2 are predominantly nuclear and partial FAK nuclear
localisation was also confirmed by immunoblot (Figure 6B).
We next investigated whether NF2 and FAK silencing additively
induces p53 expression in MESO257. The p53 expression
quantifications were normalised to control infections using empty
vector pLKO. The NF2 and FAK shRNA knockdowns resulted in
greater than 50% and 60% inhibition of expression of their targets.
The NF2 shRNA knockdown induced p53, p21, and MDM2
expression, and FAK silencing resulted in upregulation of p53, p21,
and p27. The combination of FAK and NF2 shRNA knockdowns
increased p53, MDM2, p21, and p27 expression two- to three-fold,
which was greater than the level after either intervention alone
(Figure 6C). Furthermore, we investigated p53 and p21 expression
in nuclear, cytoplasmic, and membrane fractions after NF2
knockdown (Figure 6D). The NF2 shRNA knockdown induced
p53 in each of these subcellular fractions, at levels comparable to
those in the total cell lysate. Similarly, p21 expression was induced
in the nuclear and cytoplasmic fractions, at levels comparable to
those in the total cell lysate (Figure 6D). In addition, NF2-positive
MESO257 cells demonstrated increased sensitivity to FAK shRNA
after NF2 knockdown (Figure 6E).
DISCUSSION
Mesothelioma is a fatal malignancy most often associated with
asbestos exposure. Currently available therapies, which involve
aggressive surgery, radiation, and chemotherapy, have done little to
improve the prognosis of patients with this cancer. Incomplete
understanding of mesothelioma biology has hindered the devel-
opment of more effective therapeutics. Evidence indicates that
activation of tyrosine kinases is essential in the progression from
nonneoplastic mesothelial progenitor cells to mesothelioma. p53, a
tumour suppressor, has a crucial role in the cellular responses to a
variety of stresses, such as hypoxia or DNA damage, through its
accumulation in the nucleus (Levine, 1997; Oren, 1999). Inactivat-
ing TP53 mutations are found in approximately 50% of human
tumours (Hollstein et al, 1991). However, TP53 mutations are seen
less frequently in mesothelioma (Metcalf et al, 1992; Papp et al,
2001). Previous studies have suggested that p53 activity is
potentially lost in mesothelioma because of p14ARF inactivation
and the effects of the SV40 large T antigen (Testa and Giordano,
2001; Yang et al, 2001). However, the role of SV40 in
mesothelioma carcinogenesis and the frequency of SV40 presence
in mesothelioma have been questioned (Lopez-Rios et al, 2004;
Whitson and Kratzke, 2006). Furthermore, recent studies indicate
that p53 is functional in the absence of p14ARF and can induce
apoptosis in mesothelioma (Hopkins-Donaldson et al, 2006). Thus,
the identification of TK–p53 interactions and their functional
evaluation in mesothelioma provides an opportunity to identify
novel therapeutic strategies.
The interaction of tyrosine kinases and the p53 family was first
reported by investigating the association of c-Abl and p73a in
apoptosis (Agami et al, 1999). In the present study, we identified a
tyrosine kinase, FAK, that is highly expressed in mesothelioma,
and investigated potential interactions of FAK with p53. Although
interaction between FAK and p53 was shown previously by a
biochemical approach (Golubovskaya et al, 2005), it is still unclear
whether the FAK–p53 interaction may also have a crucial role in
tumour biology. In previous studies, we developed and validated a
functional proteomic approach including double phosphotyrosine
and panRTK immuno-affinity purification, coupled to tandem
mass spectrometry in various tumour tissues or cell lines (Ou et al,
2011). We therefore identified the interaction of FAK–p53 in the
MESO257 cell line by the PY–p53 double purification and mass
spectrometry approach (Figure 1), and validated this interaction in
five mesothelioma cell lines by FAK and p53 immunoprecipita-
tions (Figure 3). Immunoblotting evaluations of FAK and p53
expression and phosphorylation in mesothelioma cell lines and
primary frozen tumours further demonstrated that FAK and p53
are ubiquitously expressed and constitutively activated in
mesothelioma (Figure 2), indicating that FAK–p53 pathways have
a role in mesothelioma growth. In addition, normal p53 expression
in most mesothelioma samples confirmed that TP53 mutations are
infrequent in these cancers (Figure 2).
To evaluate whether FAK–p53 interaction has crucial functional
roles in mesothelioma, FAK was silenced by lentiviral FAK shRNA
in wild-type p53 mesothelioma cell lines (MESO924, MESO257,
MESO296, and MESO428) and in the mutant p53 JMN1B line
(Figures 4 and 5A). Interestingly, FAK shRNA knockdown induced
one- to three-fold increases of p53 expression and phosphorylation
in wild-type p53 mesothelioma cell lines, which is consistent with
the level of p53 upregulation after FAK shRNA knockdown in
human fibroblasts (Lim et al, 2008). The p53 expression did not
increase after FAK inhibition at low concentrations of PF562271
(Supplementary Figure 1). Further studies showed that FAK
inhibition at high concentration of PF562271 (5 mM) induced p53
Table 1. Cell cycle analysis after treatment with 5 mM Nutlin-3, FAK shRNA, and combination in mesothelioma cell lines
MESO924 MESO257 MESO296 MESO428 JMN1B
G1/0 G2 S A G1/0 G2 S A G1/0 G2 S A G1/0 G2 S A G1/0 G2 S A
DMSO 62 10 28 0.7 53 8 39 1.8 62 7 31 0.5 52 5 43 0.3 36 15 49 6.6
Nutlin-3 68 8 24 0.8 55 24 21 2.2 79 6 15 0.6 50 2 48 1.1 36 16 48 5.1
Vector 54 6 40 1.6 52 9 39 2.6 61 6 33 0.7 48 2 50 2.1 36 15 49 4.6
FAK shRNA 64 6 30 0.9 62 12 26 2.6 70 1 29 0.8 65 1 34 0.7 40 23 37 13
DMSO & Vector 54 6 40 2.1 51 9 40 2.0 63 5 32 1.5 52 3 45 3.1 37 10 53 4.5
Nutlin-3 & FAK shRNA 62 16 22 0.5 60 30 11 3.3 68 16 16 2.3 60 12 28 4.0 43 24 33 13
Abbreviations: DMSO¼dimethyl sulphoxide; FAK¼ focal adhesion kinase; shRNA¼ short hairpin RNA. ‘A’: pre-G1. The data were obtained from Figure 5D and shown by percentage (%).
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expression because of inhibition of MDM2 and phospho-MDM2
expression (Figure 4B). These results are consistent with a FAK
kinase-independent effect for p53 expression. However, FAK
shRNA knockdown had little effect on p53 levels as compared
with vector-treated cells in mutant p53 JMN1B cells (Figure 5A).
These findings indicate that FAK negatively regulates wild-type
p53 expression.
The structure and mechanisms of the MDM2–p53 interaction
have been extensively studied (Kussie et al, 1996; Chene, 2003;
Brooks and Gu, 2006; White et al, 2006). MDM2 suppresses p53
activity by inducing nuclear export and degradation, and blocking
its transcriptional activity (Chene, 2003). Therefore, inhibition of
the wild-type p53–MDM2 interaction is an opportunity for cancer
therapeutics (Kojima et al, 2006; Tovar et al, 2006; Van et al, 2009).
In the current study, we show increased expression and
phosphorylation of p53, and decreased viability in a dose-dependent
manner after treatment with nutlin-3 in wild-type p53 cell lines
(Figure 5A and B), indicating that inhibition of MDM2–p53
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interaction has an important biological function in mesothelioma.
It has been shown that FAK–-p53 and MDM2–p53 form an
autoregulatory feedback loop (Chene, 2003; Golubovskaya et al,
2005). The FAK shRNA knockdown induced expression of p53 and
phospho-p53 (Figure 5A), which prevents association with MDM2
(Chene, 2003), but had little impact on MDM2 expression level
(Figure 5A). By contrast, nutlin-3 treatment induced MDM2 and
p53 expression, but had little effect on FAK expression in wild-type
p53 mesothelioma cell lines. Nuclear FAK acts as a scaffold to
stabilise the MDM2–p53 complex, leading to p53 polyubiquitina-
tion and subsequent p53 degradation by nuclear or cytoplasmic
proteasomes (Lim et al, 2008). Those observations suggest that a
feedback loop regulates FAK–p53–MDM2 activity. In the future,
we will further study this signalling feedback loop in the tumour
microenvironment.
The NF2 inactivation by genomic mechanisms occurs in more
than 80% of mesothelioma, as a critical step in mesothelioma
pathogenesis, and upregulates FAK activity (Bianchi et al, 1995;
Poulikakos et al, 2006). A recent study showed that mesothelioma
cells that are more sensitive to FAK inhibition lack NF2 expression
(Shapiro et al, 2014). In the present study, in NF2-null MESO924,
overexpression of mutant NF2 S518A, which mimics constitutively
phosphorylated NF2 and functions equivalently to wild-type NF2,
partially inhibited FAK activity, while overexpression of mutant,
nonfunctional NF2 S518D, did not inhibit FAK activity
(Supplementary Figure 2). The MESO257 cells showed strong NF2
expression, whereas NF2 expression was weak or nearly undetectable
in the other mesothelioma cell lines and primary frozen tumours in
this study (Figure 2), which is in keeping with previous evidence for
NF2 inactivation by genomic mechanisms in mesothelioma (Metcalf
et al, 1992; Papp et al, 2001). After treatment with nutlin-3, the FAK
inhibitor PF562271, or FAK shRNA knockdown, upregulation of p53
and phospho-p53, and reduction of cell viability were least
pronounced in NF2-positive MESO257 as compared with NF2-
inactivated cell lines (Figure 5A–C), NF2 knockdown resulted in the
accumulation of p53-p21 in nucleus and cytoplasm (Figure 6D), and
NF2-positive MESO257 cells showed increased sensitivity to FAK
shRNA after NF2 knockdown (Figure 6E), indicating that the
presence of NF2 regulates MDM2–p53 and FAK–p53 interactions.
This is in keeping with previous data demonstrating that NF2
neutralises the inhibitory effect of MDM2 on p53 (Kim et al, 2004),
that NF2 negatively regulates FAK activity (Poulikakos et al, 2006),
and that NF2 deficiency predicts increased sensitivity of mesothe-
lioma cells to a FAK inhibitor, VS-4718 (Shapiro et al, 2014). NF2-
null mesothelioma cells have been found to have weak cell–cell
adhesions (Shapiro et al, 2014), which results in FAK leaving focal
contact sites, increasing the cytoplasmic pool of FAK and enhancing
FAK nuclear accumulation (Lim et al, 2008). Nuclear FAK acts as a
scaffold to stabilise MDM2–p53 complexes, leading to p53
polyubiquitination and subsequent p53 degradation by nuclear or
cytoplasmic proteasomes (Lim et al, 2008). These observations
establish mechanisms by which FAK knockdown or FAK kinase
activity inhibition suppress cell growth via minimising p53
degradation by MDM2 (Figure 4A and B, and Figure 5A), and
have greater anti-proliferative effects in NF2-null mesothelioma cell
lines (MESO296 and MESO428) than NF2-positive MESO257 cell
lines (Figure 5B and C). Further, nuclear co-localisation of NF2,
FAK, and p53 indicate that NF2 potentially regulates the interaction
of FAK and p53 (Figure 6B). The NF2 shRNA knockdown resulted
in the upregulation of p53 and MDM2 in MESO257 (Figure 6C),
indicating that NF2 regulates the interaction of MDM2 and p53, and
that upregulation of p53 expression by MDM2 inhibition (nutlin-3)
is NF2-dependent. Focal adhesion kinase inhibits p53 through FAK
nuclear translocation, binding to p53, and enhanced MDM2-
dependent p53 ubiquitination and degradation (Lim et al, 2008).
Thus, additive effects were obtained through coordinated reactiva-
tion of p53 by FAK knockdown, which attenuated MDM2-
dependent p53 degradation, and by NF2 knockdown, which
attenuated the inhibitory effect of MDM2 on p53.
Our data indicate that FAK regulates cell survival via p53-
dependent and -independent pathways, which was demonstrated
by immunoblots after FAK knockdown in mutant p53 JMN1B cell
line and in nonmutant p53 mesothelioma cell lines (MESO924,
MESO257, MESO296, and MESO428; Figure 5). In addition, we
found the dramatic anti-proliferative and apoptotic effects of FAK
knockdown in mutant leiomyosarcoma cell lines (data not shown).
The FAK (FAK shRNA or PF562271) and MDM2 (nutlin-3)
inhibitors showed anti-proliferative effects in mesothelioma cell
lines characterised by a decrease of cyclin A expression, CDK
inhibitor p21 upregulation (Figure 5A), reduction of cellular
viability (Figure 5B and C), and G1-phase arrest (Figure 5D).
Interestingly, additive effects were obtained through a coordinated
attack on p53, as demonstrated by immunoblots, cell viability, and
cell cycle analyses, showing that FAK and MDM2 inhibition
together induced greater p53 expression, cell apoptosis, anti-
proliferative effects, and cell cycle arrest, as compared with either
intervention alone. These findings highlight novel therapeutic
opportunities in mesothelioma.
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